EULAR 2023 Lupus Highlights
Rheumnow Podcast
00:00
The Role of Bylimumab in the Development of a Novel Renal Flass
There are just over 100 patients or about 8% and developed in a denoveal renal flass. So it's nice that you're bringing up the percentage because it was actually pretty similar to what we reported a couple of years ago when we looked at real-world data coming from Sweden and from the UK together from Leeds. Yes, absolutely. And I think you touched just now about some of your, you know, it's in the key findings. Okay. The load of intravenous Bylimab and the placebo group, the respective placebo. It was striking first to see that there was a clear separation between Bylimumab 1 milligram percolum.
Transcript
Play full episode
